220 related articles for article (PubMed ID: 37679212)
21. Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia.
Ali KE; Mohammed IA; Difabachew MN; Demeke DS; Haile T; Ten Hove RJ; Kumssa TH; Woldu ZL; Haile EL; Tullu KD
BMC Cancer; 2019 Aug; 19(1):768. PubMed ID: 31382907
[TBL] [Abstract][Full Text] [Related]
22. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
23. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
24. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
25. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
26. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
27. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
28. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
29. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
Zhao Y; Bao H; Ma L; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wang HJ; Wu J
BMC Med; 2021 Jul; 19(1):164. PubMed ID: 34261463
[TBL] [Abstract][Full Text] [Related]
31. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
32. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
33. Development and evaluation of a cervical cancer screening system in Cambodia: A collaborative project of the Cambodian Society of Gynecology and Obstetrics and Japan Society of Obstetrics and Gynecology.
Ueda Y; Kawana K; Yanaihara N; Banno K; Chhit M; Uy K; Kruy L; Sann CS; Ishioka-Kanda M; Akaba H; Matsumoto Y; Fujita N; Yano T; Koum K; Okamoto A; Kimura T
J Obstet Gynaecol Res; 2019 Jul; 45(7):1260-1267. PubMed ID: 30977232
[TBL] [Abstract][Full Text] [Related]
34. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
35. HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level.
Altobelli E; Rapacchietta L; Profeta VF; Fagnano R
Cancer Med; 2019 May; 8(5):2524-2534. PubMed ID: 30993902
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
37. Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.
Obel J; McKenzie J; Buenconsejo-Lum LE; Durand AM; Ekeroma A; Souares Y; Hoy D; Baravilala W; Garland SM; Kjaer SK; Roth A
Asian Pac J Cancer Prev; 2015; 16(8):3435-42. PubMed ID: 25921158
[TBL] [Abstract][Full Text] [Related]
38. Variations in sexual and reproductive health services for the provision of comprehensive contraceptive and abortion services across Europe: A questionnaire-based study commissioned by the European Board and College of Obstetrics & Gynaecology (EBCOG) and European Society of Contraception (ESC).
Khattak H; Tsiapakidou S; Mukhopadhyay S; Mahmood T; Cameron S; Kubba A; Merki-Feld G; Savona-Ventura C; Klanjscek J; Bitzer J
Eur J Obstet Gynecol Reprod Biol; 2024 May; ():. PubMed ID: 38851960
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
40. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.
Chrysostomou AC; Stylianou DC; Constantinidou A; Kostrikis LG
Viruses; 2018 Dec; 10(12):. PubMed ID: 30572620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
